Plenary Session: Best Practices for Addressing the Health Needs of the LGBTQ+ Community in Oncology Care
In 2022, NCCN conducted a patient advocacy scan with roughly a dozen representatives from the LGBTQ+ community representing patient advocates, researchers, and healthcare providers with expertise in this area. The results of the scan found that patients who are LGBTQ+ are likely to report experiencing bias and discrimination in care which can impact their care outcomes. The scan participants also overwhelmingly highlighted a need for robust healthcare provider training in how to create inclusive care environments and practices for the LGBTQ+ community.
This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.
Following this program, participants should be able to:
- Identify challenges and barriers to access of cancer care experienced by LGTBQ+ patients.
- Review suggested solutions to improve collection of data about LGBTQ+ patients.
- Implement strategies to address challenges and barriers into clinical practice to improve inclusivity in oncology care.
Clifford Goodman, PhD (he/him)
Consultant, Health Care Technology and Policy
Bláz Bush, MEd (Bláz/he)
Stanford Medicine LGBTQ+ Health Program
Paula Chambers Raney (she/her)
Cancer Survivor; Hope Coordinator, Fight Colorectal Cancer
Shail Maingi, MD (she/her)
Dana-Farber Cancer Institute
Mandi L. Pratt-Chapman, PhD (sher/her)
GW Cancer Center
Scout, PhD (he/him/they)
National LGBT Cancer Network
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
The faculty listed below have no relevant financial relationships with ineligible companies to disclose.
Bláz Bush, MEd
Paula Chambers Raney
Clifford Goodman, PhD
The faculty listed below have the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Shail Maingi, MD
Merck & Co., Inc.: Equity Interest/Stock Options
Mandi L. Pratt-Chapman, PhD
Merck & Co., Inc.: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
Pfizer Inc.: Honoraria
Takeda Pharmaceuticals North America, Inc.: Honoraria
Bristol-Myers Squibb Company: Consulting Fee; Grant/Research Support
EMD Serono: Consulting Fee
Genentech, Inc.: Grant/Research Support
Gilead Sciences, Inc.: Grant/Research Support
GlaxoSmithKline: Grant/Research Support
Syros Pharmaceuticals: Grant/Research Support
NCCN Staff Disclosures
The planners listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Crystal S. Denlinger, MD
Agios, Inc.: Grant/Research Support
Amgen Inc.: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Grant/Research Support
BeiGene: Scientific Advisor; Grant/Research Support
Bristol-Myers Squibb Company: Scientific Advisor; Grant/Research Support
Eli Lilly and Company: Grant/Research Support
Exelixis Inc.: Grant/Research Support
Genmab: Grant/Research Support
MacroGenics: Grant/Research Support
MedImmune Inc: Grant/Research Support
Merck & Co., Inc.: Scientific Advisor
sanofi-aventis U.S.: Grant/Research Support
Taiho Pharmaceutials Co., Ltd.: Scientific Advisor
Zymeworks: Scientific Advisor; Grant/Research Support
Johnson & Johnson: Equity Interest/Stock Options
None of the other planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 1.5 contact hours.
NCCN designates this knowledge-based continuing education activity for 1.5 contact hours (0.15 CEUs) of continuing education credit. UAN: JA4008196-0000-23-059-H01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until March 1, 2024. PAs should only claim credit commensurate with the extent of their participation.
As a Jointly Accredited Organization, NCCN is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. NCCN maintains responsibility for this course. Social workers completing this course receive 1.5 continuing education credits.
- 1.50 AAPA Category 1 CME credit
- 1.50 ACPE contact hours
- 1.50 AMA PRA Category 1 Credit™
- 1.50 ANCC contact hours
- 1.50 ASWB continuing education credit
- 1.50 Participation
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing